These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 37725166)
1. Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumab. VandeVrede L; La Joie R; Horiki S; Mundada NS; Koestler M; Hwang JH; Ljubenkov PA; Rojas JC; Rabinovici GD; Boxer AL; Seeley WW Acta Neuropathol; 2023 Nov; 146(5):777-781. PubMed ID: 37725166 [No Abstract] [Full Text] [Related]
2. Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. Cummings J; Aisen P; Lemere C; Atri A; Sabbagh M; Salloway S Alzheimers Res Ther; 2021 May; 13(1):98. PubMed ID: 33971962 [No Abstract] [Full Text] [Related]
3. "Aducanumab" making a comeback in Alzheimer's disease: An old wine in a new bottle. Behl T; Kaur I; Sehgal A; Singh S; Sharma N; Makeen HA; Albratty M; Alhazmi HA; Felemban SG; Alsubayiel AM; Bhatia S; Bungau S Biomed Pharmacother; 2022 Apr; 148():112746. PubMed ID: 35231697 [TBL] [Abstract][Full Text] [Related]
4. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease. Salloway S; Chalkias S; Barkhof F; Burkett P; Barakos J; Purcell D; Suhy J; Forrestal F; Tian Y; Umans K; Wang G; Singhal P; Budd Haeberlein S; Smirnakis K JAMA Neurol; 2022 Jan; 79(1):13-21. PubMed ID: 34807243 [TBL] [Abstract][Full Text] [Related]
5. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease. Budd Haeberlein S; Aisen PS; Barkhof F; Chalkias S; Chen T; Cohen S; Dent G; Hansson O; Harrison K; von Hehn C; Iwatsubo T; Mallinckrodt C; Mummery CJ; Muralidharan KK; Nestorov I; Nisenbaum L; Rajagovindan R; Skordos L; Tian Y; van Dyck CH; Vellas B; Wu S; Zhu Y; Sandrock A J Prev Alzheimers Dis; 2022; 9(2):197-210. PubMed ID: 35542991 [TBL] [Abstract][Full Text] [Related]
6. Aducanumab: The first targeted Alzheimer's therapy. Yang P; Sun F Drug Discov Ther; 2021; 15(3):166-168. PubMed ID: 34234067 [TBL] [Abstract][Full Text] [Related]
7. Aducanumab: First Approval. Dhillon S Drugs; 2021 Aug; 81(12):1437-1443. PubMed ID: 34324167 [TBL] [Abstract][Full Text] [Related]